Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

about

Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

Item

http://www.wikidata.org/entity/Q36315170

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Impact of biochemical failure ...... y Oncology Group 9202 and 9413

@ast

Impact of biochemical failure ...... y Oncology Group 9202 and 9413

@en

type

Item

label

Impact of biochemical failure ...... y Oncology Group 9202 and 9413

@ast

Impact of biochemical failure ...... y Oncology Group 9202 and 9413

@en

prefLabel

Impact of biochemical failure ...... y Oncology Group 9202 and 9413

@ast

Impact of biochemical failure ...... y Oncology Group 9202 and 9413

@en

P1476

Impact of biochemical failure ...... y Oncology Group 9202 and 9413

@en

P2093

Charlie C Pan

http://www.w3.org/2001/XMLSchema#string

Colleen A Lawton

http://www.w3.org/2001/XMLSchema#string

Daniel A Hamstra

http://www.w3.org/2001/XMLSchema#string

Gerald Hanks

http://www.w3.org/2001/XMLSchema#string

Howard M Sandler

http://www.w3.org/2001/XMLSchema#string

Kyounghwa Bae

http://www.w3.org/2001/XMLSchema#string

William U Shipley

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

Evaluation of survival data and two new rank order statistics arising in its consideration.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer.

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413

How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?

Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.

Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

P304

844-852

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.29146

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Chen Hu

Mack Roach

P577

2014-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25410885

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

4657945

http://www.w3.org/2001/XMLSchema#string